Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL. Data demonstrate the activity and tolerability when patients are retreated with ADCETRIS, the activity and tolerability of ADCETRIS in CD30-positive non-Hodgkin lymphomas and CD30 expression from a screening protocol in non-lymphoma malignancies. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
“Our goal is for ADCETRIS to become the foundation of therapy for CD30-positive malignancies and, to that end, we are aggressively investing in its clinical development and broadly exploring CD30 expression across numerous cancer types,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Our data presentations at ASCO highlight the potential for ADCETRIS and reinforce our development strategy to generate data that will support stepwise growth of ADCETRIS for patients with CD30-expressing malignancies.”
Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study (Abstract #8027)
In a phase II trial, patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse were eligible for retreatment. Data were reported from 24 patients treated to date on the study, including 16 with Hodgkin lymphoma (HL) and eight with systemic anaplastic large cell lymphoma (sALCL). Patients had received a median of four prior systemic therapies, including ADCETRIS. Key findings include:
- Of 23 evaluable patients, 70 percent (16 of 23) achieved an objective response after retreatment with ADCETRIS, including nine complete remissions (CRs) and seven partial remissions (PRs).
- Median duration of retreatment objective response was 8.8 months.
- Among retreated HL patients, nine of 16 (56 percent) achieved an objective response. Among retreated sALCL patients, seven of eight (88 percent) achieved an objective response.
- The most common adverse events were peripheral neuropathy (46 percent), nausea (42 percent), fatigue (38 percent), diarrhea (33 percent) and fever (29 percent).
- The phase II retreatment trial is ongoing.
- Saturday, June 2; 8:00 a.m. to 1:00 p.m. Central Time (CT), with discussion from 12:00 p.m. to 1:00 p.m. CT
- Poster display in room E450b and discussion in room E354a
- First author: Dr. Nancy L. Bartlett, Washington University, Siteman Cancer Center, St. Louis, MO
- Of 14 patients evaluable for response, five patients (36 percent) achieved an objective response, including three CRs and two PRs.
- Four of seven DLBCL patients treated with ADCETRIS achieved an objective response, including two CRs and two PRs.
- Seventy-one percent of patients achieved tumor reduction.
- ADCETRIS treatment was generally well-tolerated, with the most common adverse events being fatigue (21 percent), abdominal pain (17 percent), nausea (17 percent), chills (13 percent), diarrhea (13 percent) and vomiting (13 percent).
- Enrollment is ongoing.
- Monday, June 4; 1:15 p.m. to 5:15 p.m. CT
- Poster presentation in S Hall A2; poster board #35C
- First author: Dr. Ranjana Advani, Stanford University Medical Center, Stanford, CA
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV